Primary biliary cholangitis (PBC) is a rare autoimmune liver disease that commonly affects middle-aged women. It is characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is followed by cholestasis, which causes debilitating fatigue and itch. Without adequate management, PBC culminates in liver fibrosis, cirrhosis, end-stage organ disease, and death. The goals of treatment for PBC are to halt or slow the progression of liver disease, reduce the need for liver transplantation, lower the risk of mortality, and alleviate symptoms (e.g., fatigue, itch). Ursodeoxycholic acid (UDCA) is the cornerstone of PBC treatment, and Intercept’s Ocaliva is an option for patients who respond inadequately to UDCA. Although these drugs improve outcomes, they do not address the underlying autoimmune defect or meaningfully improve the symptoms associated with PBC. As a result, most PBC patients are concurrently prescribed symptomatic treatments.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan, Intercept Pharmaceuticals, others
Key drugs: UDCA, obeticholic acid (Ocaliva), fibrates, oral corticosteroids, oral immunosuppressants, selective serotonin reuptake inhibitors, antihistamines, antiepileptic drugs, serotonin receptor antagonists